Chinese burn: new blacklists to expose healthcare company misbehaviour
This article was originally published in Scrip
Pharmaceutical companies that value their reputation in China will soon need to tread more carefully when it comes to keeping in line with local drug and device laws. From 1 October a new blacklist will publically expose misbehaving companies and their misdemeanours for patients and healthcare professionals to see.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.